| Bioactivity | SBI-425 is an orally active and potent TNAP (tissue-nonspecific alkaline phosphatase) inhibitor (IC50=16 nM). SBI-425 inhibits TNAP in the vasculature, improving cardiovascular parameters and survival[1][2]. | ||||||||||||
| Target | IC50: 16 nM (TNAP) | ||||||||||||
| Invitro | SBI-425 treatment suppresses Foxp3 expression in CD4+ and CD8+ T cells in splenocytes from CLP-injured mice[3]. | ||||||||||||
| In Vivo | 1.19Mouse PK parameters for SBI-425[1] Compds | ||||||||||||
| Name | SBI-425 | ||||||||||||
| CAS | 1451272-71-1 | ||||||||||||
| Formula | C13H12ClN3O4S | ||||||||||||
| Molar Mass | 341.77 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Pinkerton AB, et al. Discovery of 5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide (SBI-425), a potent and orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor. Bioorg Med Chem Lett. 2018 Jan 1;28(1):31-34. [2]. Sheen CR, et al. Pathophysiological role of vascular smooth muscle alkaline phosphatase in medial artery calcification. J Bone Miner Res. 2015 May;30(5):824-36. [3]. Brichacek AL, et al. Systemic inhibition of tissue-nonspecific alkaline phosphatase alters the brain-immune axis in experimental sepsis. Sci Rep. 2019 Dec 11;9(1):18788. |
SBI-425
CAS: 1451272-71-1 F: C13H12ClN3O4S W: 341.77
SBI-425 is an orally active and potent TNAP (tissue-nonspecific alkaline phosphatase) inhibitor (IC50=16 nM). SBI-425 in
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.